Ovarian seromucinous tumor
diseaseOn this page
Also known as mixed epithelial neoplasm of ovarymixed epithelial neoplasm of the ovarymixed epithelial tumor of the ovarymixed epithelial tumour of the ovaryovarian mixed epithelial neoplasmovarian Seromucinous tumour
Summary
Ovarian seromucinous tumor (MONDO:0003811) is a cancer and 1 clinical trial. Top therapeutic interventions include cisplatin and veliparib. A subtype of ovarian epithelial tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 1
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | ovarian seromucinous tumor |
| Mondo ID | MONDO:0003811 |
| DOID | DOID:6211 |
| NCIT | C4508 |
| SNOMED CT | 254855000 |
| UMLS | C0346166 |
| MedGen | 83409 |
| Is cancer (heuristic) | yes |
Also known as: mixed epithelial neoplasm of ovary · mixed epithelial neoplasm of the ovary · mixed epithelial tumor of the ovary · mixed epithelial tumour of the ovary · ovarian mixed epithelial neoplasm · ovarian Seromucinous tumor · ovarian Seromucinous tumour
Disease family
This is a subtype of ovarian epithelial tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › epithelial neoplasm › ovarian epithelial tumor › ovarian seromucinous tumor
Related subtypes (10): ovarian Brenner tumor, ovarian squamous cell neoplasm, ovarian mucinous neoplasm, ovarian papillary tumor, ovarian mucinous adenofibroma, ovarian adenoma benign, borderline epithelial tumor of ovary, malignant epithelial tumor of ovary, ovarian clear cell tumor, ovarian serous tumor
Subtypes (1): ovarian seromucinous carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 1.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00989651 | PHASE1 | COMPLETED | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CISPLATIN | 4 | 1 |
| VELIPARIB | 3 | 2 |